MiNK Therapeutics sets third-quarter results release
INKT•MiNK Therapeutics will report third-quarter 2026 results before the market opens on Nov. 11, with a conference call and webcast at 8:30 a.m. ET.
1. Results and webcast
MiNK Therapeutics plans to review its results and clinical development priorities during the Nov. 11 call. The update will cover agenT-797’s randomized Phase 2 evaluation, scalable cell therapy technologies and cancer treatment programs.
